NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
Clinical Trials
11 trialsNCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04648475 2023-04-18
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04649983 2023-04-18
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT04016129 2019-09-19
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03166878 2017-06-23
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02963038 2017-04-28
CAR T Cells for Refractory B Cell Malignancy
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT02672501 2016-02-03
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown